Sirtex sees sales of SIR-Spheres ascend

Sirtex (ASX:SRX) saw its stock bump by 2.5% to $5.45 in afternoon trading after announcing this morning that it has experienced its 27th consecutive quarter of dose sales growth of its anti-liver cancer treatment, SIR-Spheres.

Dose sales of the targeted radioactive treatment grew 20.7% for the quarter ending 31 March 2011 compared to the same quarter last year.

Year-to-date dose sales were up 18%, compared to 14.7% for the first three quarters of FY2010.

The fastest-growing market was Europe, up 23% compared to the same quarter last year, with US sales up 20% and Asia Pacific up 13%.

Revenue for FY2010 was $64.3 million, with a market cap of $304 million as of today.

The company posted a net profit of $3.6 million for the first half of FY2011, which is down 61% year-on-year due to the strong Australian dollar and increased costs, including higher prices from ANSTO of radiopharmaceuticals.